Programme

13.30	“Investor and Analyst Track”	“Compliance” Presented by KPMG AG	“Emerging Companies” Presented by Bayer	“Impacts on the value chain” Presented by S-GE
08:30	Registration opens
09:00	Exhibition and Partnering throughout the day
10:00	General Assembly of the Swiss Biotech Association (by invitation only)
	Plenary Session
11:00	Welcome Address Domenico Alexakis, CEO, Swiss Biotech Association
11:10	Key Note I: Transforming Chemistry Rudolf Hanko, CEO, Siegfried AG
11:30	Key Note II: Innovation@Bayer: Combining Creative Minds With Passion Monika Lessl, Head of Innovation Strategy, Bayer AG
11:50	Presentation of the Swiss Biotech Report and Panel Discussion Jürg Zürcher, Ernst & Young AG and Member of the Steering Committee
12:30	Lunch
	Santhera Pharmaceuticals Holding Ltd. Thomas Meier, CEO Newron Pharmaceuticals S.p.A. Stefan Weber, CEO Addex Therapeutics Timothy Dyer, CFO InnoMedica AG Jonas Zeller, Head of Finance Molecular Partners Andreas Emmenegger, CFO Probiodrug Konrad Glund, CEO Nordic Nanovector Luigi Costa, CEO	The right balance between too much and too little – compliance – get inspired Martin Rohrbach, Partner & Head of Audit Basel, KPMG AG Impact of emerging regulations, codes and guidelines on how biotech companies conduct business Kathleen Tench, Director Forensic, KPMG AG When does compliance become a management principle? Peter Herrmann, CCO Actelion Pharmaceuticals Ltd. Compliance program for early research functions Jan Wesiack, Regional Compliance Manager Europe, NIBR Basel, Novartis Pharma AG Research with Human Biological Material and Data Adrian Zumbach, Senior Legal Counsel at Novartis Institutes of BioMedical Research (NIBR), Novartis Pharma AG Structuring the insurance portfolio of Life Science Companies Jörg Schmidt, Schmidt Versicherungs Treuhand AG Ethics as a business case for the right balance in compliance Martijn de Kiewit, Director Forensic, KPMG AG	Genkyotex SA Elias Papatheodorou, CEO Quartz Bio SA Jérôme Wojcik, CEO Gour Medical SA Serge Goldner, CEO Tolerys SA Pierre-Marie Guyonvarc'h, CEO Inthera Bioscience Ulrich Kessler, CEO Chrondonest Thierry Schwitzguébel Memo-Therapeutics Armin W. Mäder, CEO MaxiVax Nicolas Mach, CSO	Introduction on Value Chains in Biotech Hans Mies, Director Intl. Corporate Tax at KPMG AG, value chain management expert New Markets: International Cooperations Jakob Dynnes Hansen, CFO, Evolva New Markets – benefits of international R&D cooperation Andreas Gut, Swiss EUREKA Project Coordinator, State Secretariat for Education, Research and Innovation SERI Innovation: Technology Fusion: Biotech meets IT Arthur Queval, Founder & CEO, Qloudlab Processes and Structures: Lean and mean: Biotech structures in Switzerland Panel Discussion Moderation: Monika Jones
17.00	Apéro and Wrap-Up of the Day - hosted by Bayer AG
19.00	End

Programme Track “Compliance”

Presented by KPMG

Speakers to be defined.

13.30 - 13.45	Intro – The value of compliance?	Martin Rohrbach

13.45 - 15.00	Session 1 Impact of emerging regulations, codes and guidelines on how biotech companies conduct business Regulatory: Sunshine Act, Human Research Law & Nagoya Protocol Key Findings from KPMG’s Global Anti-Bribery and Corruption Survey Clinical research compliance a competitive advantage?	Kathy Tench

15.30 - 17.00	Session 2 Ethics as a business case: having the right strategy	Martijn de Kiewit

Programme Track “Impacts on the value chain”

Presented by S-GE

Introduction on Value Chains in Biotech
New Markets International Cooperations
Innovation Technology Fusion: Biotech meets IT
Processes and Structures Lean and mean: Biotech structures in Switzerland
Panel Discussion

Moderation: Monika Jones